Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression

被引:342
作者
Bobrovitz, Niklas [1 ,3 ,4 ]
Ware, Harriet [4 ]
Ma, Xiaomeng [2 ]
Li, Zihan [4 ,5 ]
Hosseini, Reza [4 ,6 ]
Cao, Christian [1 ,4 ]
Selemon, Anabel [4 ]
Whelan, Mairead [4 ]
Premji, Zahra [7 ]
Issa, Hanane [8 ]
Cheng, Brianna [1 ]
Abu Raddad, Laith J. [9 ]
Buckeridge, David L. [10 ]
Van Kerkhove, Maria D. [11 ]
Piechotta, Vanessa [12 ]
Higdon, Melissa M. [13 ]
Wilder-Smith, Annelies [14 ,15 ]
Bergeri, Isabel [11 ]
Feikin, Daniel R. [14 ]
Arora, Rahul K. [4 ,16 ]
Patel, Minal K. [14 ]
Subissi, Lorenzo [11 ]
机构
[1] Univ Toronto, Temerty Fac Med, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[3] Arras Hosp, Dept Crit Care Med, Arras, France
[4] Univ Calgary, Ctr Hlth Informat, Cumming Sch Med, Calgary, AB, Canada
[5] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA USA
[6] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada
[7] Univ Victoria, Lib, Victoria, BC, Canada
[8] UCL, Inst Hlth Informat, London, England
[9] Cornell Univ, Infect Dis Epidemiol Grp, Weill Cornell Med Qatar, Doha, Qatar
[10] McGill Univ, Sch Populat & Global Hlth, Dept Epidemiol & Biostat, Montreal, PQ, Canada
[11] WHO, Hlth Emergencies Programme, Geneva, Switzerland
[12] Robert Koch Inst, Dept Infect Dis Epidemiol, Berlin, Germany
[13] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Int Vaccine Access Ctr, Baltimore, MD USA
[14] WHO, Dept Immunizat Vaccines & Biol, Geneva, Switzerland
[15] Heidelberg Univ, Heidelberg Inst Global Hlth, Heidelberg, Germany
[16] Univ Oxford, Inst Biomed Engn, Oxford, England
关键词
VACCINATION; DURATION;
D O I
10.1016/S1473-3099(22)00801-5
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background The global surge in the omicron (B.1.1.529) variant has resulted in many individuals with hybrid immunity (immunity developed through a combination of SARS-CoV-2 infection and vaccination). We aimed to systematically review the magnitude and duration of the protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against infection and severe disease caused by the omicron variant.Methods For this systematic review and meta-regression, we searched for cohort, cross-sectional, and case-control studies in MEDLINE, Embase, Web of Science, ClinicalTrials.gov, the Cochrane Central Register of Controlled Trials, the WHO COVID-19 database, and Europe PubMed Central from Jan 1, 2020, to June 1, 2022, using keywords related to SARS-CoV-2, reinfection, protective effectiveness, previous infection, presence of antibodies, and hybrid immunity. The main outcomes were the protective effectiveness against reinfection and against hospital admission or severe disease of hybrid immunity, hybrid immunity relative to previous infection alone, hybrid immunity relative to previous vaccination alone, and hybrid immunity relative to hybrid immunity with fewer vaccine doses. Risk of bias was assessed with the Risk of Bias In Non-Randomized Studies of Interventions Tool. We used log-odds random effects meta-regression to estimate the magnitude of protection at 1-month intervals. This study was registered with PROSPERO (CRD42022318605).Findings 11 studies reporting the protective effectiveness of previous SARS-CoV-2 infection and 15 studies reporting the protective effectiveness of hybrid immunity were included. For previous infection, there were 97 estimates (27 with a moderate risk of bias and 70 with a serious risk of bias). The effectiveness of previous infection against hospital admission or severe disease was 74 & BULL;6% (95% CI 63 & BULL;1-83 & BULL;5) at 12 months. The effectiveness of previous infection against reinfection waned to 24 & BULL;7% (95% CI 16 & BULL;4-35 & BULL;5) at 12 months. For hybrid immunity, there were 153 estimates (78 with a moderate risk of bias and 75 with a serious risk of bias). The effectiveness of hybrid immunity against hospital admission or severe disease was 97 & BULL;4% (95% CI 91 & BULL;4-99 & BULL;2) at 12 months with primary series vaccination and 95 & BULL;3% (81 & BULL;9-98 & BULL;9) at 6 months with the first booster vaccination after the most recent infection or vaccination. Against reinfection, the effectiveness of hybrid immunity following primary series vaccination waned to 41 & BULL;8% (95% CI 31 & BULL;5-52 & BULL;8) at 12 months, while the effectiveness of hybrid immunity following first booster vaccination waned to 46 & BULL;5% (36 & BULL;0-57 & BULL;3) at 6 months.Interpretation All estimates of protection waned within months against reinfection but remained high and sustained for hospital admission or severe disease. Individuals with hybrid immunity had the highest magnitude and durability of protection, and as a result might be able to extend the period before booster vaccinations are needed compared to individuals who have never been infected.
引用
收藏
页码:556 / 567
页数:12
相关论文
共 40 条
  • [1] Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
    Altarawneh, Heba N.
    Chemaitelly, Hiam
    Ayoub, Houssein H.
    Tang, Patrick
    Hasan, Mohammad R.
    Yassine, Hadi M.
    Al-Khatib, Hebah A.
    Smatti, Maria K.
    Coyle, Peter
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed G.
    Butt, Adeel A.
    Al-Romaihi, Hamad E.
    Al-Thani, Mohamed H.
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (01) : 21 - 34
  • [2] Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
    Altarawneh, Heba N.
    Chemaitelly, Hiam
    Hasan, Mohammad R.
    Ayoub, Houssein H.
    Qassim, Suelen
    AlMukdad, Sawsan
    Coyle, Peter
    Yassine, Hadi M.
    Al-Khatib, Hebah A.
    Benslimane, Fatiha M.
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed G.
    Butt, Adeel A.
    Al-Romaihi, Hamad E.
    Al-Thani, Mohamed H.
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Tang, Patrick
    Abu-Raddad, Laith J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (13) : 1288 - 1290
  • [3] Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
    Andeweg, Stijn P.
    de Gier, Brechje
    Eggink, Dirk
    van den Ende, Caroline
    van Maarseveen, Noortje
    Ali, Lubna
    Vlaemynck, Boris
    Schepers, Raf
    Hahne, Susan J. M.
    Reusken, Chantal B. E. M.
    de Melker, Hester E.
    van den Hof, Susan
    Knol, Mirjam J.
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [4] Adverse Events Following One Dose of mRNA COVID-19 Vaccination Among US Nursing Home Residents With and Without a Previous SARS-CoV-2 Infection
    Bardenheier, Barbara H.
    Gravenstein, Stefan
    Blackman, Carolyn
    Gutman, Roee
    Sarkar, Indra Neil
    Feifer, Richard A.
    White, Elizabeth M.
    McConeghy, Kevin
    Nanda, Aman
    Bosco, Elliott
    Mor, Vincent
    [J]. JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2021, 22 (11) : 2228 - 2232
  • [5] Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies
    Bergeri, Isabel
    Whelan, Mairead G.
    Ware, Harriet
    Subissi, Lorenzo
    Nardone, Anthony
    Lewis, Hannah C.
    Li, Zihan
    Ma, Xiaomeng
    Valenciano, Marta
    Cheng, Brianna
    Al Ariqi, Lubna
    Rashidian, Arash
    Okeibunor, Joseph
    Azim, Tasnim
    Wijesinghe, Pushpa
    Linh-Vi Le
    Vaughan, Aisling
    Pebody, Richard
    Vicari, Andrea
    Yan, Tingting
    Yanes-Lane, Mercedes
    Cao, Christian
    Clifton, David A.
    Cheng, Matthew P.
    Papenburg, Jesse
    Buckeridge, David
    Bobrovitz, Niklas
    Arora, Rahul K.
    Van Kerkhove, Maria D.
    [J]. PLOS MEDICINE, 2022, 19 (11)
  • [6] Berkey CS, 1998, STAT MED, V17, P2537, DOI 10.1002/(SICI)1097-0258(19981130)17:22<2537::AID-SIM953>3.0.CO
  • [7] 2-C
  • [8] COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA. 2 subvariants - surveillance results from southern Sweden, December 2021 to March 2022
    Bjork, Jonas
    Bonander, Carl
    Moghaddassi, Mahnaz
    Rasmussen, Magnus
    Malmqvist, Ulf
    Inghammar, Malin
    Kahn, Fredrik
    [J]. EUROSURVEILLANCE, 2022, 27 (18) : 8 - 13
  • [9] Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study
    Bruel, Timothee
    Pinaud, Laurie
    Tondeur, Laura
    Planas, Delphine
    Staropoli, Isabelle
    Porrot, Francoise
    Guivel-Benhassine, Florence
    Attia, Mikael
    Pelleau, Stephane
    Woudenberg, Tom
    Duru, Cecile
    Koffi, Aymar Davy
    Castelain, Sandrine
    Fernandes-Pellerin, Sandrine
    Jolly, Nathalie
    De Facci, Louise Perrin
    Roux, Emmanuel
    Ungeheuer, Marie-Noelle
    Van der Werf, Sylvie
    White, Michael
    Schwartz, Olivier
    Fontanet, Arnaud
    [J]. ECLINICALMEDICINE, 2022, 51
  • [10] Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses
    Buckner, Clarisa M.
    Kardava, Lela
    El Merhebi, Omar
    Narpala, Sandeep R.
    Serebryannyy, Leonid
    Lin, Bob C.
    Wang, Wei
    Zhang, Xiaozhen
    Assis, Felipe Lopes de
    Kelly, Sophie E. M.
    Teng, I-Ting
    McCormack, Genevieve E.
    Praiss, Lauren H.
    Seamon, Catherine A.
    Rai, M. Ali
    Kalish, Heather
    Kwong, Peter D.
    Proschan, Michael A.
    McDermott, Adrian B.
    Fauci, Anthony S.
    Chun, Tae-Wook
    Moir, Susan
    [J]. CELL, 2022, 185 (23) : 4333 - +